Related Experiment Video
Updated: Mar 30, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
14.5K
Direct factor Xa inhibitor edoxaban: from bench to clinical practice
Mpa Brekelmans1, S Middeldorp2, M Coppens3
1a Department of Vascular Medicine F4-146 , Academic Medical Center , Amsterdam , The Netherlands.
Expert Review of Hematology
|November 13, 2015
Summary
Edoxaban, a direct factor Xa inhibitor, offers effective stroke prevention in atrial fibrillation and venous thromboembolism treatment. It provides similar thromboembolic protection to warfarin with a reduced bleeding risk.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Edoxaban is a novel direct oral anticoagulant (DOAC) targeting factor Xa.
- It is the fourth DOAC approved for clinical use.
- DOACs represent a significant advancement in anticoagulant therapy.
Purpose of the Study:
- To review the key characteristics of edoxaban.
- To summarize the clinical evaluation program for edoxaban's regulatory approval.
- To highlight edoxaban's role in stroke prevention and VTE management.
Main Methods:
- Review of large Phase III randomized controlled trials.
- Analysis of clinical data supporting regulatory submissions.
- Comparison of edoxaban with warfarin and other anticoagulants.
Main Results:
- Edoxaban demonstrated reduced bleeding risk compared to warfarin.
- It provided comparable protection against thromboembolic events.
- Phase III trials formed the basis for its approval in AF and VTE.
Conclusions:
- Edoxaban is a valuable addition to anticoagulation therapies.
- Its once-daily dosing and specific dose adjustments enhance its utility.
- Limitations include specific renal clearance criteria and initial heparin use for acute VTE.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:29Venous Thrombosis III: Interprofessional Care
465
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
656
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
656
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
87
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
87